Opinion: On Global GMO Regulation

Advances in genome-editing technologies have made modifying crops easier than ever before. They’ve also clouded the already murky realm of genetically modified foods.

Written byTetsuya Ishii
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

USDA, KEITH WELLERGenome-editing technologies—including zinc finger nuclease (ZFN), transcription activator-like effector nuclease (TALEN), and CRISPR/Cas tools—have facilitated various gene modifications even in higher organisms. Meanwhile, advanced genetic engineering raises a worldwide regulatory issue by creating indistinct boundaries in genetically modified organism (GMO) regulations because, without introducing new genetic material, genome editing can be used to make modifications similar to naturally occurring mutations. To encourage public discussion on the regulatory issue, my colleagues and I last year presented a general drawing of the complicated regulatory issue in Trends in Biotechnology. Now, in an article published in Trends in Plant Science this week (February 25), Motoko Araki and I focus on genome-edited crops in the context of global GMO regulation.

First, we analyzed 13 research articles of genetically modified varieties of barley, rice, sweet orange, wheat, soybean, corn, and tomato. We found that rice was the most frequently modified of all major crops. The most common modification types of all crops studied were mutations with a few bases deleted or inserted (indels), resulting in modified crops that resemble naturally occurring mutants. The genes targeted for mutation had been selected for the purposes such as introducing herbicide resistance, increasing nutritional value, and changing flavor. Although gene modification efficiency varies between target genes, in some cases, it can reach up to 40 percent. Genome editing may induce off-target mutations in plant genomes, which might be associated with health and environmental risks. However, less than half of the ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies